Immunophenotype of tumor-infiltrating lymphocytes in atypical Spitzoid tumors according to the risk of progression.


Journal

Annals of diagnostic pathology
ISSN: 1532-8198
Titre abrégé: Ann Diagn Pathol
Pays: United States
ID NLM: 9800503

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 04 03 2022
revised: 23 05 2022
accepted: 03 06 2022
pubmed: 17 6 2022
medline: 19 10 2022
entrez: 16 6 2022
Statut: ppublish

Résumé

The aims of the study were to investigate and compare the immunophenotype of tumor-infiltrating lymphocytes (TILs) and PD-L1 expression in a series of benign, intermediate and malignant Spitzoid lesions showing marked inflammatory lymphoid component, to find out its possible relation with the prognosis of these lesions. Six out of 97 Spitz nevus (SN) (6 %), five out of 26 atypical Spitz tumors (AST) (16 %) and seven out of 37 Spitzoid melanomas (SM) (19 %) showed diffuse, intense inflammatory component and were included in the study. The biological risk of the tumors was assessed in all AST through the melanoma 4 probe-FISH assay and the 9p21 locus exploration. TILs were quantitatively immunophenotyped using CD3, CD4, CD8, CD20, TIA1, FOXP3 and PD1 antibodies. PD-L1 was assessed in tumoral cells and inflammatory cells adjacent to the tumor. No significant differences of TILs immunophenotype were found between SN, AST and SM. However, the classification of tumors according to the biological risk showed that grouped SN plus low-risk AST had a significantly higher number of T-cells CD8+ and TIA-1+, as well as a lower CD4/CD8 relation and B- lymphocyte number than high-risk of progression tumors (grouped high-risk AST plus SM). Immunoregulatory T-cell markers PD1 and FOXP3 only correlated with each other and with PD-L1 expression. In conclusion, The TILs immunoprofile differences between low-risk and high-risk of progression Spitzoid tumors, especially regarding CD8 and the cytotoxic immune response, can add prognostic information about these challenging tumors and impact the clinical management of patients.

Identifiants

pubmed: 35709617
pii: S1092-9134(22)00087-9
doi: 10.1016/j.anndiagpath.2022.151985
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
Forkhead Transcription Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151985

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflict of interest to declare.

Auteurs

Irene Moysset (I)

Department of Pathology, Consorci Sanitari Integral, Av. Josep Molins, 29, 08906, L'Hospitalet de Llobregat, Barcelona, Spain; University of Barcelona, Villarroel 170, 08036, Barcelona, Spain. Electronic address: Irene.moysset@sanitatintegral.org.

Carla Fuster-Anglada (C)

Department of Pathology, Hospital Clinic of Barcelona, Villarroel 170, 08036, Spain. Electronic address: FUSTER@clinic.cat.

Paola Castillo (P)

University of Barcelona, Villarroel 170, 08036, Barcelona, Spain; Department of Pathology, Hospital Clinic of Barcelona, Villarroel 170, 08036, Spain. Electronic address: pcastill@clinic.cat.

Cristina Teixido (C)

Department of Pathology, Hospital Clinic of Barcelona, Villarroel 170, 08036, Spain; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Casanova 143, 08036 Barcelona, Spain. Electronic address: teixido@clinic.cat.

Adriana Garcia-Herrera (A)

University of Barcelona, Villarroel 170, 08036, Barcelona, Spain; Department of Pathology, Hospital Clinic of Barcelona, Villarroel 170, 08036, Spain; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Casanova 143, 08036 Barcelona, Spain. Electronic address: APGARCIA@clinic.cat.

Marta Marginet (M)

Department of Pathology, Hospital Clinic of Barcelona, Villarroel 170, 08036, Spain. Electronic address: mmarginet@clinic.cat.

Ingrid Lopez (I)

Department of Pathology, Hospital Clinic of Barcelona, Villarroel 170, 08036, Spain. Electronic address: ilopezs@clinic.cat.

Dolors Costa (D)

Department of Pathology, Hospital Clinic of Barcelona, Villarroel 170, 08036, Spain. Electronic address: dcosta@clinic.cat.

Cristina Carrera (C)

University of Barcelona, Villarroel 170, 08036, Barcelona, Spain; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Casanova 143, 08036 Barcelona, Spain; Department of Dermatology, Hospital Clínic of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain. Electronic address: ccarrera@clinic.cat.

Ana Arance (A)

Department of Oncology, Hospital Clínic of Barcelona, Villarroel 170, 08036 Barcelona, Spain. Electronic address: amarance@clinic.cat.

Llucia Alos (L)

University of Barcelona, Villarroel 170, 08036, Barcelona, Spain; Department of Pathology, Hospital Clinic of Barcelona, Villarroel 170, 08036, Spain; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Casanova 143, 08036 Barcelona, Spain. Electronic address: lalos@clinic.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH